Loading...
  • plerixafor
  • AUTHORS' CONCLUSIONS: The results of the analysed data suggest that additional plerixafor leads to increased stem cell collection in a shorter time. (uzh.ch)
  • HSCs
  • Nevertheless, high dose therapy with reinfusion of HSCs is commonly used in the hematopoietic malignancies, and if the transduction efficiency can be improved then the therapeutic possibilities are great, limited only by the number of useful genes available. (biomedcentral.com)
  • remission
  • After a median follow-up of 72 (60-80) months, 18 (82%) patients achieved completed remission, one (5%) patient achieved partial remission, and one patient had no response and received peritoneal dialysis at 12 months after transplantation. (asnjournals.org)
  • PBSC
  • Thus, in this patient population, organ function and host and hematopoietic factors influence engraftment after PBSC rescue. (nih.gov)
  • engraftment
  • In a multivariate analysis, the factors positively affecting the rate of neutrophil engraftment were CD34+ stem cell dose, female gender, and minimal prior alkylator therapy. (nih.gov)
  • Crohn's
  • Even more encouraging, there are stem cell resources in the body that can treat the underlying cause of Crohn's disease. (mystemcellusa.com)